It was a pleasure to speak with Dr Klaus Rabe (Lung Clinic Großhansdorf and The University of Kiel, Germany) around the rationale for the use of dupilumab in GINA-defined difficult to-treat type 2 asthma patients (Clinical Trial Identifier: NCT02414854).
The abstract ‘Dupilumab Efficacy in GINA-Defined Difficult To-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST Study.’ (ABSTRACT NUMBER: 183) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
- Could you tell us a little about dupilumab and the clinical evidence supporting its use in asthma patients? (0:52)
- How do the recent Global Initiative for Asthma (GINA) guidelines define difficult to treat and severe asthma? (3:38)
Disclosures: Klaus Rabe has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
Share this Video
Related Videos In Asthma
Andrew Menzies-Gow, ERS 2021: Personalised Treatment for Severe Asthma
It was a pleasure to meet with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to talk around personalised treatment and emerging hot topics in severe asthma. Questions How can we further personalise treatment for people with severe asthma? (0:11) What are the hot topics and latest research you are looking […]
Andrew Menzies-Gow, ERS 2021: Benralizumab Following Oral Corticosteroid Reduction in Severe Asthma
TouchRESPIRATORY got the opportunity to catch up with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to discuss oral corticosteroid (OCS) dependency in severe asthma and the use of benralizumab following OCS reduction. The abstract ‘Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study.’ (ID:1460) was presented at […]
Sarah Diver, ATS 2021: The CASCADE Study
TouchRESPIRATORY got the opportunity to catch up with Dr Sarah Diver (University of Leicester, Leicester, UK) around the CASCADE study, investigating the use of tezepelumab in patients with moderate-to-severe uncontrolled asthma. ‘Effect of tezepelumab on airway inflammatory cells, remodeling and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma: a randomized, double-blind, placebo-controlled trial’ was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!